Table 1.
Clinical characteristics of 186 control patients from the discovery cohort.
Table 2.
Characteristics of the 100 patients from the prospective validation cohort.
Fig 1.
A. Fumigatus-specific T cell detection by ELISpot assay in patients with proven IA and controls, discovery cohort.
Box plot showing immune responses producing IFN-γ and IL-10 in patients with proven IA (n = 20) and controls (n = 186). Individual data points for each patient are shown. Results are expressed as the number of SFC per 106 PBMCs. Mean with SD is given. * = P<0.05.
Fig 2.
Receiver-operating characteristic (ROC) analyses to derive cut-offs.
ROC analysis was performed between the cases with proven IA versus control group to determine the cut-off level that yielded the maximum sensitivity plus specificity, according to the presence of Aspergillus-specific T cells producing IL-10. aROC = 0.8953 (95% confidence interval: 0.80–0.99); optimal criterion ≥ 40; sensitivity: 89.5%; specificity: 88.6%. aROC = area under the ROC curve.
Fig 3.
Study design flow chart, discovery cohort.
Abbreviations: HRCT high resolution computed tomography; EORTC European Organization for Research and Treatment of Cancer; MSG Mycoses Study Group; SFCs Spot Forming Cells. * Dense, well-circumscribed lesions with or without a halo sign, air crescent sign, cavity, wedge-shaped and segmental or lobar consolidation. § One out of 51 samples excluded from the analysis because not informative.
Table 3.
Diagnostic concordance between 2019 EORTC/MSG and ELISpot.
Fig 4.
A. fumigatus-specific T-cell responses in patients showing ELISpot positivity.
Column graphs represent the values of T cells producing IFN-γ and IL-10 at different time-points. Chest HRCT (High-Resolution Computed Tomography) images show the radiologic evolution during the course of the infection.